Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany
This study evaluated factors that influence the cost-effectiveness of talazoparib, particularly for patients with a germline breast-cancer-gene-(brca)-mutation and locally advanced or metastasized breast cancer within the context of the German healthcare system. We constructed a partitioned survival...
Main Authors: | Florian Schwarz, Habibollah Arefian, Michael Hartmann, Ingo Runnebaum |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2022-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714746/?tool=EBI |
Similar Items
-
Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany.
by: Florian Schwarz, et al.
Published: (2022-01-01) -
885 Characterization of the tumor microenvironment in advanced breast cancer patients treated with talazoparib followed by combination of talazoparib and avelumab
by: Edward T Richardson, et al.
Published: (2023-11-01) -
Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer
by: Florian G. Klein, et al.
Published: (2021-04-01) -
Combination of Talazoparib and Calcitriol Enhanced Anticancer Effect in Triple−Negative Breast Cancer Cell Lines
by: Fu Hou Wong, et al.
Published: (2022-08-01) -
Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers
by: Xuan Liu, et al.
Published: (2022-05-01)